What we're reading, November 18, 2015: global drug spending is expected to grow 30% in 5 years; Robert M. Califf, MD, sits through mostly friendly senate confirmation hearing for FDA nomination; and moderate coffee consumption could reduce some risks of death.
Global Drug Spending Will Hit $1.3 Trillion in 2020
Sharp increases in drug spending it not an American phenomenon. According to an IMS Health report, global spending on medicines will rise between 3% and 6% annually over the next 5 years. The increase, to global spending of about $1.3 trillion in 2020, will be driven by expensive new drugs, price hikes, and aging populations. The spending increased would have been more except for a wave of patent expirations for expensive brand-name drugs during that time, the AP reported.
FDA Nominee Dr Califf Breezes Through Senate Committee
Robert M. Califf, MD, a cardiologist, clinical trial expert from Duke University, consultant to drug companies, and President Barack Obama’s nominee to lead the FDA came under scrutiny for his industry ties during his 2-hour hearing with the Senate Committee on Health, Education, Labor and Pensions, reported the New York Times. However, largely, the committee seemed to support his candidacy with the only exceptions being Elizabeth Warren (D-MA) and Bernie Sanders (I-VT), the presidential hopeful.
Moderate Coffee Consumption Reduces Risk of Death
Need a little coffee to get your day started? People who drink moderate amounts of coffee—between 1 and 5 cups a day—had a lower risk of mortality compared with people who don’t drink any coffee, according to a study in Circulation. Coffee consumption was associated with decreased risk of deaths due to cardiovascular disease, neurological diseases, and suicide. However, there was no associated decrease risk in mortality from cancer.
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More